Canadian microultrasound technology developer Exact Imaging is highlighting initial clinical results published in the Journal of Urology for its prostate risk identification microultrasound (PRI-MUS) protocol with its ExactVu platform.
The study, led by Dr. Sangeet Ghai at Princess Margaret Cancer Centre in Toronto, found that the protocol helped detect significant disease using microultrasound for real-time visualization of suspicious lesions and to guide biopsies (J Urol, August 2016, Vol. 196:2, pp. 562-569).
Exact Imaging plans to seek CE Mark approval and clearance from the U.S. Food and Drug Administration (FDA) for ExactVu in the coming months, the company said.
